Published in Int J Cancer on December 15, 2009
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Gastrointestinal stromal tumors. Virchows Arch (2010) 2.28
Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer (2012) 1.08
Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer (2010) 1.08
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.08
Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol (2013) 1.08
Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res (2011) 0.92
Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol (2013) 0.91
Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol (2014) 0.90
Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Cancer Med (2013) 0.84
Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours. Eur J Cancer (2012) 0.80
The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine (2014) 0.80
Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J Hematol Oncol (2013) 0.79
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res (2010) 0.79
qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. BMC Mol Biol (2010) 0.78
The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med (2010) 0.78
Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: it is time to define it. World J Gastroenterol (2013) 0.78
Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med (2015) 0.77
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clin Sarcoma Res (2016) 0.75
Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours - an analysis of 70 cases from 2004 to 2010. Prz Gastroenterol (2015) 0.75
Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol (2015) 0.75
Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs (2015) 0.75
Gastrointestinal stromal tumor and its targeted therapeutics. Chin J Cancer (2011) 0.75
The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors. Chin J Cancer (2017) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol (2002) 4.09
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73
Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Gastrointestinal stromal tumour. Lancet (2007) 3.25
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol (2011) 2.72
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol (2008) 2.68
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol (2009) 2.57
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol (2008) 2.38
Does acute alcoholic pancreatitis precede the chronic form or is the opposite true? A histological study. J Clin Gastroenterol (2004) 2.28
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol (2002) 2.22
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res (2008) 2.03
Effectiveness of sentinel lymph node intraoperative examination in 753 women with breast cancer: are we overtreating patients? Ann Surg (2012) 2.02
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study. Scand J Gastroenterol (2009) 1.99
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer (2009) 1.94
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94
Esophagogastric junction gastrointestinal stromal tumor: resection vs enucleation. World J Gastroenterol (2010) 1.92
Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn (2012) 1.92
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res (2003) 1.87
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83
RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A (2009) 1.81
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res (2006) 1.76
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells (2006) 1.72
Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res (2003) 1.70
Surgery versus conservative antibiotic treatment in acute appendicitis: a systematic review and meta-analysis of randomized controlled trials. Dig Surg (2011) 1.67
2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg (2013) 1.65
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood (2008) 1.64
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev (2008) 1.56
SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst (2011) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Clin Cancer Res (2009) 1.52
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus (2007) 1.51
Laparoscopic treatment of gastric GIST: report of 21 cases and literature's review. J Gastrointest Surg (2007) 1.48
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat (2009) 1.45
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol (2008) 1.45
In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene (2005) 1.44
Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer. Acta Cytol (2006) 1.42
A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest (2010) 1.42
Phytosterol supplementation reduces metabolic activity and slows cell growth in cultured rat cardiomyocytes. Br J Nutr (2011) 1.41
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood (2011) 1.40
Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg (2010) 1.39
STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol (2002) 1.38
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep (2010) 1.38
KIT mutations are common in testicular seminomas. Am J Pathol (2004) 1.36
The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol (2002) 1.35